Table 3 Multivariate analysis on the effect of ICI within 90 days.
From: Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases
Variable | N | Events | Cox multivariable hazard ratio (95% CI) | Cox multivariable Wald p-value |
|---|---|---|---|---|
ICI status | ||||
No-ICI | 325 | 247 (76%) | 1.87 (1.30, 2.68) | < 0.001 |
ICI-90 | 68 | 39 (57%) | – | |
Sex | ||||
Female | 187 | 130 (70%) | 1.02 (0.79, 1.32) | 0.87 |
Male | 206 | 156 (76%) | – | |
Age | ||||
< 65 | 232 | 158 (68%) | – | |
≥ 65 | 161 | 128 (80%) | 1.302 (1.013, 1.674) | 0.039 |
KPS | ||||
< 90 | 178 | 138 (78%) | 1.69 (1.28, 2.23) | < 0.001 |
≥ 90 | 141 | 93 (66%) | – | |
Unknown | 74 | 55 (74%) | 0.93 (0.64, 1.34) | 0.69 |
SRS | ||||
0–1 | 284 | 218 (77%) | 2.08 (1.52, 2.85) | < 0.001 |
≥ 2 | 98 | 60 (61%) | – | |
Histology | ||||
Other | 106 | 88 (83%) | 1.39 (1.07, 1.82) | 0.014 |
Adenocarcinoma | 268 | 184 (69%) | – | |
EC-mets | ||||
No | 207 | 144 (70%) | – | |
Yes | 176 | 135 (77%) | 1.31 (1.02, 1.68) | 0.035 |
Lesion number | ||||
1 | 201 | 140 (70%) | – | |
≥ 2 | 190 | 144 (76%) | 1.38 (1.07, 1.78) | 0.012 |
